(UroToday.com) At the 2021 American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, during the session entitled “Breaking Barriers: Ensuring Equity in Cancer Diagnosis, Treatment, and Trial Enrollment for Patients with Kidney and Bladder Cancers,” Dr. Chana Weinstock presented the role of the FDA to create a regulatory environment to encourage diversity in the modern era of genitourinary oncology trials.